Back
December 2, 2021

"Like a soldier who only starts loading his weapon once he has arrived on the battlefield"

Q&A with Geert Vanden Bossche #2

Question:

I am a nurse in CT. Can you tell me, if we have received the vaccination, what should we do to support our immune system now? Will our immune system ever return to normal or clear from the MRNA vaccines?

Answer:

The problem is, after a full vaccination regimen, your immune system became truly primed. This is to say; the vaccine generated immunological memory. Once a fully vaccinated individual gets re-exposed, vaccinal Abs will rapidly be recalled and mount at high concentration. Under normal circumstances (i.e., outside of a pandemic of viral variants) this recall provides you with fast protection. And even if the virus undergoes some change, one can always immunize later on with an ‘updated’ vaccine (e.g., in case of Flu). However, as public health authorities have given the greenlight to conducting mass vaccination campaigns, in the middle of a pandemic (!), the virus (SARS-CoV-2) is now continuously put under high immune pressure, while still able to transmit. This inevitably leads to a non-stop selection and adaptation of more infectious variants. Those will not be adequately contained by updated vaccines, regardless of what Industry and PH authorities try to make people believe.

First and foremost, updated vaccines will recall the old Abs (due to ‘antigenic sin’) and subsequently, generated ‘updated’ Abs will be produced while the vaccinee is already under attack from the virus. (As we are dealing with a pandemic of highly infectious variants: Delta and now Omicron!). For the latter, I always refer to a soldier who only starts loading his weapon once he has arrived on the battlefield (i.e., while already under attack of the enemy). This makes it easy for the enemy (the virus) to escape from the soldier (the immune system). So, in other words, C-19 vaccines, whether updated or not, will not provide you with protective Abs for much longer (Loss of protection against
severe disease is just going to be a matter of ‘some’ more time).

In the meantime, the Abs induced by the vaccine will still be able to outcompete relevant innate Abs for binding to the virus. These innate Abs would normally, if not suppressed, protect you against C-19 disease provided you’re in good health (remember: C-19 disease is not normally a disease of healthy people, let alone children!). Of course, vaccinal Ab titers wane over time but in the current situation, with highly infectious Delta and now Omicron soon circulating, it is nearly impossible not to get re-exposed to the virus for a prolonged period of time. That is why I keep emphasizing: the single most important immediate measure is to replace detrimental mass vax campaigns by mass vax antiviral chemoprophylaxis campaigns (just for 6-8 weeks) to bring down the infectious pressure.

This would prevent vaccinees from receiving ‘natural’ boosters as a result of re-exposure. And would enable the unvaccinated (unfortunately, now becoming an absolute minority!) to further reduce the infection rates (without being at risk for contracting C-19 disease) thanks to their intact innate immunity. As the latter provides sterilizing immunity, the unvaccinated can then help the vaccinated to become less and less exposed. Therefore, reducing their risk of contracting severe C-19 disease - as a result of infection with a vaccine-resistant virus. Alternatively, vaccinees could be treated with a sterilizing vaccine which kills virus-infected cells at an early stage of infection (i.e., before viral
progeny is released from infected host cells and triggers boosting of vaccinal Abs by B memory cells). This could be achieved by NK cell-based vaccines. Such an approach is, anything, but supported by the Vaccine Industry.

Support our work
DONATE
Subscribe to our Substack Newsletter

Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.

Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.

Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.

Email: info@voiceforscienceandsolidarity.org

Recent Posts
May 25, 2022

VSS Scientific Updates During Pandemic Times #22

Read
May 23, 2022

VSS Scientific Updates During Pandemic Times #21

Read
May 17, 2022

Q&A #13: Why do Public Health authorities continue to promote C-19 vaccination of children?

Read
Voices for Science and solidarity, © 2021